As per Market Research Future Analysis, the Global Dravet Syndrome Market was valued at USD 0.55 Billion in 2023 and is projected to grow to USD 0.94 Billion by 2032, with a CAGR of 9.31% from 2024 to 2032. Key drivers include increasing healthcare costs in affluent nations, enhanced regulatory environments, and rising adoption rates of new treatments. The prevalence of Dravet syndrome, affecting 1 in 15,700 newborns in the U.S., alongside recent FDA approvals for medications like Stiripentol and Epidiolex, further supports market growth. The market is segmented by seizure type, treatment methods, and diagnostic approaches, with hospitals being the dominant end-user segment.
The Dravet Syndrome market is witnessing significant growth driven by advancements in treatment and diagnosis.
Biocodex, Biscayne Neurotherapeutics, Cyberonics, Epygenix Therapeutics, GW Pharmaceuticals, INSYS THERAPEUTICS, OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics.
The Dravet Foundation reports that 1 in 15,700 newborns born in the United States have Dravet syndrome. Stiripentol (Diacomit), a medication approved by the Food and Drug Administration (FDA), treats Dravet syndrome in kids two years of age and older who also receive clobazam. Epidiolex (cannabidiol), the first FDA-approved medication containing a refined drug ingredient derived from marijuana, was also approved by the FDA in June 2018. Because more research and Development are being done, these latest approvals are helping the market's quick expansion even more. These elements are projected to support the market CAGR for Dravet syndrome.
Recent regulatory approvals for managing and treating the illness are one of the major market factors boosting the Dravet syndrome industry. Stiripentol (Diacomit) and epidiolex are two medications that have recently received regulatory clearance for treating several disorder-related symptoms. It is also predicted that several more recent applications for regulatory approval, including the submission of a new drug application (NDA) by Zogenix for its therapeutic candidate ZX008 (Fintepla), will aid in the market's fast expansion. In addition, several medication candidates are going through various phases of clinical studies.
The manufacture of medical equipment and the Development of high-tech research centers have grown significantly in recent years. Every professional physician needs better in-hand equipment to execute the right treatment for the patients, regardless of whether the laboratory requires testing equipment or surgical accessories. As a result, various areas are currently concentrating on producing many industrial units to satisfy such needs. Many businesses also continually work to produce new pharmaceutical and medical products for the market and better patient care facilities. Due to this occurrence, the worldwide market also considerably expanded. Therefore, such a factor will drive the Dravet Syndrome market revenue growth.
The Dravet Syndrome Market segmentation is based on the type of seizures, myoclonic, partial, and absence seizures. The partial seizures segment held the majority share in 2022, contributing around ~65-67% concerning the Dravet Syndrome Market revenue. The main goal of treating people with Dravet syndrome is to decrease seizure frequency. Hence, either clobazam or valproic acid is used as the first line of treatment for the condition. PTC Therapeutics, Inc. and Zogenix, Inc are developing medicines for this.
Based on Treatment and Management, the Dravet Syndrome Market segmentation includes seizure medications, a ketogenic diet, and vagus nerve stimulation. The Seizure medications segment dominated the market in 2022 and is projected to be the faster-growing segment during 2024-2032. Due to several important benefits, including a decrease in drug-drug interactions, a decrease in life-threatening adverse events, and a less detrimental effect on cognitive functioning, second-generation antiepileptic medications are anticipated to have the biggest market share. Also, the increase in epilepsy cases will increase the demand for medications in this market niche. The segment's expansion is also fueled by the introduction of new medications for treating epilepsy by various market participants. Moreover, Dr. Reddy's Laboratories introduced the antiepileptic medication Vigabatrin tablets to the American market in February 2021 after gaining permission from the US Food and Drug Administration. Hence, the rising use of medicine for Dravet Syndrome positively impacts market growth.
Based on Diagnosis, the global Dravet Syndrome industry has been segmented by MRI, EEG, and SCN1A testing. MRI held the largest segment share in 2022, owing to the rapid adoption of advanced Dravet Syndrome surgery products and the availability of skilled medical staff. The MRI market is expanding due to improvements in diagnostic methods, including open MRI, visualization software, and superconducting magnets. Most of the most recent improvements in MRI technology relate to the software.
Figure 1: Dravet Syndrome Market, by Diagnosis, 2023 & 2032 (USD billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
End-user has bifurcated the Dravet Syndrome Market data into Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic & research institutes And Others. The Hospitals segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Patients with conditions being treated in hospitals with modern infrastructure and sufficient amenities make up most of the pool. According to estimates, the hospital pharmacy segment holds most of the market. An increasing percentage of epilepsy patients are treated in hospitals due to a growing number of hospitals and acceptable reimbursement policies offered by these settings, among other things. This ultimately led to hospital pharmacies all around the world using antiepileptic medications.
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Dravet Syndrome market accounted for USD 0.22 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The market in the area is distinguished by greater rates of neurological disease diagnosis and treatment and suitable reimbursement policies for epilepsy medications. These elements, together with greater patient population knowledge of novel treatment choices and the availability of cutting-edge epilepsy medications in the area, account for the Region's leading market share worldwide. Furthermore, the supremacy of the North American area is mostly attributable to greater spending on R&D.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: DRAVET SYNDROME MARKET SHARE BY REGION 2023 (%)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Europe Dravet Syndrome market shares the second-highest growth during the forecast period 2022. Nonetheless, it is anticipated that the increased frequency of epileptic diseases in these areas and the expanding healthcare infrastructure will drive demand for Dravet Syndrome throughout the anticipated time frame. The presence of major players, an increase in per capita disposable income, improved healthcare infrastructure, the availability of skilled medical staff, and an increase in government spending on the Development of new and effective seizure medications are all predicted to contribute to the market's revenue growth during the forecast period. Further, the German Dravet Syndrome market held the largest market share, and the UK Dravet Syndrome market was the fastest-growing market in the European Region region.
Japan is anticipated to offer the biggest market opportunity in the Asia Pacific Dravet Syndrome market. This results from the disorder's rising public profile, ongoing R&D initiatives, and the prevalence of the condition in the nation. The demand for anticonvulsant medications in Europe is expected to increase between 2019 and 2026 due to increasing ant-epilepsy therapies gaining CE mark approvals in 2019 and 2020. The revenue from the epilepsy medications market in Europe is anticipated to increase over the forecast period due to anticipated regulatory approvals in the area and the expansion of major players. Moreover, the China Dravet Syndrome market held the largest market share, and the India Dravet Syndrome market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for Dravet syndrome. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their global presence. To grow and remain in a market that is becoming increasingly competitive, Dravet Syndrome industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business tactics used by the Dravet Syndrome industry to serve customers and increase the market sector. The Dravet Syndrome industry has recently given medicine some of the most important advantages. The Dravet Syndrome market major player such Biocodex, Biscayne Neurotherapeutics, Cyberonics, Epygenix Therapeutics, GW Pharmaceuticals, INSYS THERAPEUTICS, OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, and others are working on expanding the market demand by investing in research and development activities.
A company Zogenix business that specializes in creating medications to treat illnesses of the rare central nervous system, pain, and inflammation. The new drug application (NDA) for Zogenix's treatment of Dravet syndrome was submitted in February 2019; fenfluramine medication at low dosage is used for treating the seizures associated with Dravet syndrome.
Precision medicine that is driven by genomics that focuses on and treats genetic illnesses and disorders is being developed by Encoded Therapeutics. A medicinal compound called ETX101 is currently being studied by Encoded Therapeutics. The trial aims to assess the efficacy and safety of ETX101 in patients with SCN1A-positive Dravet syndrome between the ages of 6 and 36 months. Phases 1-2 are underway, and completion is anticipated in 2029. Just one intracerebral injection of ETX101 is recommended. ETX101, a designed transcription factor, and a GABAergic regulatory element are included in the non-replicating, recombinant adeno-associated viral vector serotype 9. This combination promotes the transcription of the SCN1A gene. The approval of the medicine is anticipated to increase demand for Dravet syndrome therapy.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.55 billion |
| Market Size 2024 | USD 0.59 billion |
| Market Size 2032 | USD 0.94 billion |
| Compound Annual Growth Rate (CAGR) | 9.31% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Operating Platforms, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Biocodex, Biscayne Neurotherapeutics, Cyberonics, Epygenix Therapeutics, GW Pharmaceuticals, INSYS THERAPEUTICS, OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics |
| Key Market Opportunities | · Development of new drugs and therapies · Rising R&D expenditure |
| Key Market Dynamics | · Increasing costs for healthcare in wealthy nations · Enhancing the regulatory environment · Raising the adoption rate · Increased financing and reimbursement procedures |
Frequently Asked Questions (FAQ):
The Dravet Syndrome Market size was valued at USD 0.55 Billion in 2023.
The global market is projected to grow at a CAGR of 9.31% during the forecast period, 2024-2032.
North America had the largest share of the global market
The key players in the market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Epygenix Therapeutics, GW Pharmaceuticals, INSYS THERAPEUTICS, OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics.
The anterior Dravet Syndrome category dominated the market in 2022.
The hospital category had the largest share of the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
